ScreenerHero

GENO Genovis AB (publ.)

STO · SE · Healthcare · Biotechnology · genovis.com
19.78SEK+1.23%Mkt Cap: 127.63M $P/E: 65.93

Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia. The company provides FabRICATOR, FabALACTICA, FabRICATOR Z, GingisKHAN, FabULOU…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated - Common Stock
$127.85BUSDP/E 29.4
MRNA
Moderna, Inc. - Common Stock
$75.86BUSD
REGN
Regeneron Pharmaceuticals, Inc. - Common Stock
$75.69BUSDP/E 18.2
ARGX
argenx SE - American Depositary Shares
$57.51BUSDP/E 35.1
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc. - Common Stock
$44.29BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines Ltd. - American Depositary Shares
$40.51BUSDP/E 63.9
RPRX
Royalty Pharma plc - Class A Ordinary Shares
$33.03BUSDP/E 30.7
ALNY
Alnylam Pharmaceuticals, Inc. - Common Stock
$29.40BUSDP/E 38.3
ROIV
Roivant Sciences Ltd. - Common Shares
$25.80BUSD
BNTX
BioNTech SE - American Depositary Shares
$24.34BUSD
INSM
Insmed Incorporated - Common Stock
$24.27BUSD
INCY
Incyte Corporation - Common Stock
$23.37BUSDP/E 14.7
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
GMAB
Genmab A/S - American Depositary Shares
$21.69BUSDP/E 27.4
JAZZ
Jazz Pharmaceuticals plc - Ordinary Shares
$15.30BUSDP/E 16.1
ASND
Ascendis Pharma A/S - Ordinary Share
$14.99BUSDP/E 17.8
EXEL
Exelixis, Inc. - Common Stock
$14.47BUSDP/E 18.4
SMMT
Summit Therapeutics Inc. - Common Stock
$13.37BUSD

Key Statistics

Company
Market Cap127.63M USD
Enterprise Value117.93M USD
Revenue (TTM)13.00M USD
Gross Profit11.08M USD
Net Income (TTM)2.25M USD
Revenue/Share2.05 SEK
Last Price19.78 SEK
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees42
CountrySE
SectorHealthcare
IndustryBiotechnology
ISINSE0002485979
Valuation
P/E (Trailing)65.93
P/E (Forward)41.57
PEG—
EV/EBITDA37.44
EV/Revenue9.07
P/S9.70
P/B4.28
EPS (TTM)0.30
EPS (Forward)0.47
52W Range
15.6447% of range24.50
52W High24.50 SEK
52W Low15.64 SEK
Profitability
Gross Margin89.85%
Oper. Margin9.41%
EBITDA Margin24.24%
Profit Margin18.22%
ROE8.65%
ROA6.22%
Growth
Revenue Growth18.90%
Earnings Growth-74.70%
Cash Flow & Leverage
Operating CF3.06M USD
CapEx (TTM)1.20M USD
FCF Margin22.17%
FCF Yield2.26%
Net Debt-8.15M USD
Net Debt/EBITDA-2.59
Balance Sheet
Debt/Equity0.27
Current Ratio5.76
Quick Ratio4.44
Book Value/Sh4.57 SEK
Cash/Share2.33 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 SEK
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateApr 4, 2012
Analyst Consensus
Rating—
Target (Mean)33.00 SEK
Upside (mean)+66.8%
Target Range28.00 SEK – 38.00 SEK
28.00+66.8% to mean38.00
# Analysts2
Ownership
Shares Out.67.46M
Float56.60M
Insiders16.79%
Institutions37.70%
Technical
SMA 5020.02 (-1.2%)
SMA 20019.56 (+1.1%)
Beta1.73
S&P 52W Chg14.58%
Avg Vol (30d)157.99K
Avg Vol (10d)390.23K
Technical Indicators
RSI (14)48.2
MACD-0.3556
MACD Signal-0.3072
MACD Hist.-0.0484
BB Upper21.55 SEK
BB Middle19.79 SEK
BB Lower18.03 SEK
BB Width17.76%
ATR (14)0.7925 SEK
Vol Ratio (20d)1.36x